Drug
HU 211 clinical trials
Also written Dexanabinol and ETS2101.
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2012 | 2 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 1
e-Therapeutics PLC (2) · Santosh Kesari, M.D., Ph.D. (1) · Pharmos (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antiemetics source
- One of Neuroprotective Agents source
Studies
Open first, then newest update. How each study uses HU 211 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Dexanabinol in Patients With Brain CancerCompletedPhase 1Santosh Kesari, M.D., Ph.D.NCT01654497Written as Dexanabinol
- A Phase 1 Study of Dexanabinol in Patients With Advanced Solid TumoursCompletedPhase 1e-Therapeutics PLCNCT01489826Written as Dexanabinol
- Assessment of Single Doses of Oral Dexanabinol in Healthy SubjectsCompletedPhase 1e-Therapeutics PLCNCT02054754Written as Dexanabinol Dose Level 1
- Dexanabinol in Severe Traumatic Brain InjuryCompletedPhase 3PharmosNCT00129857Written as Dexanabinol
Given in every arm · 1 — HU 211 is usual care beside what is tested
Codes
What other systems call HU 211 · ClinicalTrials.gg INT003475
- MeSH (NLM) C062018HU 211Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) R6VT8U5372DEXANABINOLConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C062018 | HU 211 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | R6VT8U5372 | DEXANABINOL | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.